Serotonin 2A receptor antagonists for treatment of schizophrenia.
about
Multiple D2 heteroreceptor complexes: new targets for treatment of schizophreniaBrexpiprazole: so far so goodAntipsychotic dosing: found in translationDrug models of schizophreniaManganese-enhanced magnetic resonance imaging reveals increased DOI-induced brain activity in a mouse model of schizophrenia.Brain connectivity studies in schizophrenia: unravelling the effects of antipsychotics.Regulating prefrontal cortex activation: an emerging role for the 5-HT₂A serotonin receptor in the modulation of emotion-based actions?Exercise benefits brain function: the monoamine connectionStriatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response modelSerotonin: from top to bottom.Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.Clozapine, a fast-off-D2 antipsychotic.Serotonin and brain function: a tale of two receptorsThe impact of genetics on future drug discovery in schizophrenia.Clozapine as a Model for Antipsychotic Development.Attenuation of acute d-amphetamine-induced disruption of conflict resolution by clozapine, but not α-flupenthixol in rats.Differences in 5-HT2A and mGlu2 Receptor Expression Levels and Repressive Epigenetic Modifications at the 5-HT2A Promoter Region in the Roman Low- (RLA-I) and High- (RHA-I) Avoidance Rat Strains.Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients.Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia.The antipsychotic landscape: dopamine and beyond.Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomoto
P2860
Q26747736-177BC964-A123-434D-B46F-1BD4D82839C1Q26766401-B30B6D5D-3A48-45C3-AABB-455576A49668Q26863343-CEDBFA8A-B8A9-493B-B6BC-CC2EA2391472Q28084198-FE1D143C-EE54-45B4-821B-31838FF410D5Q30581184-6735BDE9-0C0E-476A-9D59-949B80B6FEC7Q30596256-C9A83EE3-A585-4777-B06B-07F3B71AC85AQ30630506-088D6693-5427-44C3-8EE2-BFEB6E0A07A9Q33772106-592AE6A8-7D63-4405-85B1-B68C9CE5A07FQ35950793-077EBE49-4B36-4D00-B126-53A93567DC66Q36950595-515FE515-E87D-47CC-AC3E-244C36D72DFBQ37125668-212C5C77-D040-4FBC-9A0A-62FC2B5F0E70Q38055710-165C6E73-BB7A-4A31-BAEE-A8ADAC2B4F92Q38062443-EB346FDE-652E-47B3-90ED-4CC3BD113E84Q38081485-8F815391-4F80-4783-876D-F480A94A19B0Q38161938-0302CE59-47F7-43EA-A11B-1222553AF3F2Q38600048-8C9C3BCA-6AFE-437B-9C87-E371AC071C39Q38682213-A2D4C582-4142-43AC-B839-BFD67D68185CQ39400094-F051082C-16B5-4ECE-B989-4BD7AAD365DDQ44854895-F9B94233-39A3-4DC8-B182-ED01287A8E47Q45054111-0B239FAE-3059-40F3-A42F-6734107FE3D9Q47173322-AA30F19D-FD30-47D9-982A-5A11E892D586Q48165414-1ABBF87C-784D-41C4-98A2-C702300879B1Q53076152-2B7891DF-061A-4B9D-8497-02F5157AA5A7Q55265863-31733C62-10DA-4954-B4AF-859954013A9E
P2860
Serotonin 2A receptor antagonists for treatment of schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@en
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@nl
type
label
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@en
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@nl
prefLabel
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@en
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@nl
P2093
P2860
P921
P1476
Serotonin 2A receptor antagonists for treatment of schizophrenia.
@en
P2093
Bjørn H Ebdrup
Hans Rasmussen
P2860
P304
P356
10.1517/13543784.2011.601738
P407
P577
2011-07-08T00:00:00Z